[Adverse drug reactions of strontium ranelate(Protelos(®) in France].

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Presse medicale

• Publication date

  2011-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lpm.2011.07.010PMID 21885232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hemorheological changes with strontium ranelate treatment do not seem to be related to its claimed prothrombotic effects.

  2012cited by this paper
• Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis.

  2011cited by this paper
• The DRESS syndrome: a literature review.

  2011cited by this paper
• Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

  2011cited by this paper
• Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

  2010cited by this paper
• [Rash and renal failure secondary to strontium ranelate].

  2010cited by this paper
• [Impact of a health safety warning on strontium ranelate utilization].

  2010cited by this paper
• Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.

  2010cited by this paper
• Severe acute hepatitis in the DRESS syndrome: Report of two cases.

  2010cited by this paper
• Incidence of Venous Thromboembolism in Users of Strontium Ranelate

  2010cited by this paper
• Impacto de una alerta sanitaria sobre la utilización de ranelato de estroncio

  2010cited by this paper
• Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study

  2010cited by this paper
• Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat

  2010cited by this paper
• Severe exfoliative dermatitis caused by strontium ranelate: two cases of a new drug reaction.

  2010cited by this paper
• Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure.

  2009cited by this paper
• Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.

  2009cited by this paper
• STRONTIUM RANELATE AS A CAUSE OF ACUTE RENAL FAILURE AND DRESS SYNDROME

  2009cited by this paper
• Strontium ranelate may cause alopecia

  2009cited by this paper
• Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

  2009cited by this paper
• Strontium ranelate‐induced DRESS syndrome: first two case reports

  2009cited by this paper
• Generalized cutaneous drug eruption due to strontium ranelate

  2009cited by this paper
• Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.

  2009cited by this paper
• Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.

  2009cited by this paper
• Bullous DRESS in a patient on strontium ranelate

  2009cited by this paper
• Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women

  2008cited by this paper
• Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis

  2008cited by this paper
• Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

  2008cited by this paper
• Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

  2007cited by this paper
• Quelle est la durée optimale des traitements dans l'ostéoporose postménopausique ?

  2007cited by this paper
• Short-Term Hemostatic Safety of Strontium Ranelate Treatment in Elderly Women with Osteoporosis

  2007cited by this paper
• Under-Reporting of Adverse Drug Reactions

  2006cited by this paper
• Le ranélate de strontium, nouvelle possibilité de traitement de l’ostéoporose post-ménopausique

  2004cited by this paper
• Strontium ranelate--a novel therapy for osteoporosis or a permutation of the same?

  2004cited by this paper
• Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study

  1997cited by this paper
• Homocystéine et maladie thromboembolique veineuse : une nouvelle approche du risque thrombotique veineux

  1997cited by this paper
• Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France

  1985cited by this paper

• Synthesis and Characterization of a Strontium–Quercetin Complex and Its In Vitro and In Vivo Potential for Application in Bone Regeneration

  2025cites this paper
• A rare case of strontium induced dermatitis in an osteoporotic patient taking an over-the-counter supplement: a case study

  2025cites this paper
• Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases

  2025cites this paper
• Strontium/Silicon/Calcium‐Releasing Hierarchically Structured 3D‐Printed Scaffolds Accelerate Osteochondral Defect Repair

  2024cites this paper
• Strontium citrate associated drug reaction with eosinophilia and systemic symptoms syndrome with granulomatous dermatitis

  2021cites this paper
• Austalide K from the Fungus Penicillium rudallense Prevents LPS-Induced Bone Loss in Mice by Inhibiting Osteoclast Differentiation and Promoting Osteoblast Differentiation

  2021cites this paper
• Carotid Stenosis under Strontium Ranelate

  2021cites this paper
• Bichasic calcium phosphate bioceramic materials influence on osteoporotic bone biomechanical parameters and bone density (experimental research). Summary of the Doctoral Thesis

  2021cites this paper
• Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta

  2021cites this paper
• Do antiosteoporotic drugs improve bone regeneration in vivo?

  2019cites this paper
• Review Venous Thromboembolism Risk with Anti-Osteoporosis Drugs

  2018cites this paper
• Systemic administration of strontium ranelate to enhance the osseointegration of implants: systematic review of animal studies

  2018cites this paper
• Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK

  2018cites this paper
• Interventions and Management of Complications of Osteoporosis

  2017cites this paper
• DRESS syndrome with autoimmune hepatitis from strontium ranelate.

  2016cites this paper
• [SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update].

  2015cites this paper
• Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización

  2015cites this paper
• Adecuación de ranelato de estroncio tras alertas de farmacovigilancia en un área de gestión sanitaria

  2015cites this paper
• Effects of thirty elements on bone metabolism.

  2015cites this paper
• Metallodrugs in medicinal inorganic chemistry.

  2014cites this paper
• Screening, diagnosis and treatment of osteoporosis: a brief review.

  2014cites this paper
• Osteoporosis: The Need for Prevention and Treatment

  2014cites this paper
• Chapter 22 – Metals

  2014cites this paper
• Strontium ranelate: in search for the mechanism of action

  2013cites this paper
• Is there potential for strontium ranelate in the management of osteoarthritis

  2013cites this paper
• L'ostéoporose : état des lieux, perspectives et rôle du pharmacien d'officine dans sa prise en charge

  2012cites this paper
• des lieux, perspectives et r^ ole du pharmacien d'ocine dans sa prise en charge

  2012cites this paper
• [Strontium ranelate(Protelos®): who really benefits of the doubt?].

  2011cites this paper
• Overview of the management of low bone mass and osteoporosis in postmenopausal women

  year unknowncites this paper